Merus Labs International (TSE:MSL) Stock Rating Reaffirmed by HC Wainwright

Merus Labs International (TSE:MSL) (NASDAQ:MSLI)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Monday, Zacks.com reports. HC Wainwright also issued estimates for Merus Labs International’s Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.22) EPS.

Merus Labs International Stock Performance

The stock’s fifty day moving average is C$1.65. Merus Labs International has a 1 year low of C$0.95 and a 1 year high of C$1.76.

Merus Labs International (TSE:MSL) (NASDAQ:MSLI) last posted its quarterly earnings data on Wednesday, March 27th. The specialty pharmaceutical company reported C($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.01) by C($0.05).

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.